Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Sells $248,530.00 in Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Mva Investors, Llc sold 29,000 shares of the business’s stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $8.57, for a total value of $248,530.00. Following the sale, the insider now owns 314,524 shares of the company’s stock, valued at approximately $2,695,470.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mva Investors, Llc also recently made the following trade(s):

• On Monday, July 1st, Mva Investors, Llc sold 110,731 shares of Tango Therapeutics stock. The stock was sold at an average price of $8.87, for a total value of $982,183.97.
• On Thursday, June 6th, Mva Investors, Llc sold 63,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $7.24, for a total value of $456,120.00.
• On Friday, May 3rd, Mva Investors, Llc sold 60,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $7.61, for a total value of $456,600.00.
• On Wednesday, May 1st, Mva Investors, Llc sold 75,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $7.43, for a total transaction of $557,250.00.

Tango Therapeutics Stock Performance

Shares of TNGX opened at $8.34 on Friday. Tango Therapeutics, Inc. has a 52-week low of $2.88 and a 52-week high of $13.03. The firm has a market cap of $891.13 million, a price-to-earnings ratio of -7.38 and a beta of 0.83. The business’s fifty day moving average is $7.89 and its 200-day moving average is $9.26.

Tango Therapeutics (NASDAQ:TNGX) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.04). Tango Therapeutics had a negative net margin of 299.88% and a negative return on equity of 44.35%. The business had revenue of $6.47 million during the quarter, compared to analyst estimates of $7.13 million. As a group, research analysts forecast that Tango Therapeutics, Inc. will post -1.31 EPS for the current fiscal year.

Institutional Investors Weigh In On Tango Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Boxer Capital LLC boosted its position in Tango Therapeutics by 15.1% in the fourth quarter. Boxer Capital LLC now owns 8,198,642 shares of the company’s stock valued at $81,167,000 after buying an additional 1,075,000 shares in the last quarter. Mass General Brigham Inc bought a new stake in Tango Therapeutics during the 1st quarter worth $2,812,000. Fisher Asset Management LLC bought a new stake in Tango Therapeutics during the 4th quarter worth $997,000. Charles Schwab Investment Management Inc. increased its holdings in Tango Therapeutics by 205.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 367,357 shares of the company’s stock worth $4,136,000 after purchasing an additional 247,234 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its position in Tango Therapeutics by 47.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 1,754,852 shares of the company’s stock valued at $19,760,000 after purchasing an additional 564,971 shares during the last quarter. 78.99% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on TNGX shares. Wedbush decreased their target price on shares of Tango Therapeutics from $18.00 to $11.00 and set an “outperform” rating on the stock in a research report on Thursday, May 23rd. Barclays reduced their price target on Tango Therapeutics from $18.00 to $13.00 and set an “overweight” rating on the stock in a research report on Friday, May 24th. HC Wainwright dropped their price objective on Tango Therapeutics from $16.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, May 28th. Cantor Fitzgerald began coverage on Tango Therapeutics in a report on Thursday, April 4th. They set an “overweight” rating on the stock. Finally, Guggenheim raised Tango Therapeutics to a “strong-buy” rating in a research note on Tuesday, May 28th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $14.17.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.